Latest Ratios: P/E Ratio -5.7x · EV/EBITDA 21.9x · ROE -167.5%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $227M | $201M | $282M | $340M | $360M | $217M | $286M | $34M | $7M | $13M | $4M |
| Enterprise Value | $259M | $233M | $298M | $347M | $352M | $199M | $286M | $30M | $7M | $13M | $5M |
| P/E Ratio → | -5.69 | — | — | — | — | — | — | — | — | 65.08 | — |
| P/S Ratio | 2.20 | 1.95 | 3.25 | 5.24 | 7.85 | 8.99 | 18.36 | 2.92 | 1.12 | 1.99 | 0.80 |
| P/B Ratio | 36.05 | 33.96 | 7.24 | 7.63 | 8.62 | 7.20 | 49.00 | 5.37 | 5.86 | 122.09 | — |
| P/FCF | 105.13 | 93.17 | — | — | — | — | — | — | 24.25 | — | 10.80 |
| P/OCF | 33.47 | 29.67 | — | — | — | — | — | — | 23.51 | — | 10.72 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.26 | 3.44 | 5.34 | 7.67 | 8.23 | 18.36 | 2.53 | 1.25 | 2.10 | 0.94 |
| EV / EBITDA | 21.92 | 19.73 | — | — | — | — | — | — | — | 65.92 | — |
| EV / EBIT | 28.30 | 25.47 | — | — | — | — | — | — | — | 28.93 | — |
| EV / FCF | — | 107.80 | — | — | — | — | — | — | 27.11 | — | 12.73 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.1% | 90.1% | 90.6% | 87.9% | 86.1% | 90.4% | 89.6% | 89.7% | 91.3% | 87.2% | 82.9% |
| Operating Margin | 8.9% | 8.9% | -7.7% | -6.5% | -27.3% | -30.6% | -32.3% | -23.3% | -8.6% | 1.9% | -4.9% |
| Net Profit Margin | -36.4% | -36.4% | -11.2% | -6.6% | -17.3% | -32.8% | -27.9% | -23.9% | -10.3% | 5.3% | -7.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -167.5% | -167.5% | -23.1% | -10.0% | -22.1% | -44.0% | -71.2% | -75.0% | -98.9% | 323.1% | — |
| ROA | -46.7% | -46.7% | -11.9% | -6.4% | -16.3% | -34.3% | -41.6% | -39.7% | -22.8% | 15.1% | -23.3% |
| ROIC | 14.8% | 14.8% | -9.5% | -7.5% | -41.3% | -62.2% | -97.5% | -109.3% | -27.7% | 15.0% | -55.8% |
| ROCE | 14.4% | 14.4% | -10.1% | -7.8% | -31.8% | -40.2% | -68.2% | -49.3% | -36.6% | 27.4% | -76.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 8.13 | 8.13 | 0.83 | 0.26 | 0.02 | 0.01 | 0.08 | 0.33 | 1.35 | 11.70 | — |
| Debt / EBITDA | 4.08 | 4.08 | — | — | — | — | — | — | — | 5.97 | — |
| Net Debt / Equity | — | 5.33 | 0.42 | 0.15 | -0.20 | -0.60 | 0.00 | -0.71 | 0.69 | 7.19 | — |
| Net Debt / EBITDA | 2.68 | 2.68 | — | — | — | — | — | — | — | 3.66 | — |
| Debt / FCF | — | 14.63 | — | — | — | — | — | — | 2.86 | — | 1.93 |
| Interest Coverage | 1.35 | 1.35 | -2.17 | -8.33 | -48.95 | -11242.03 | -384.60 | -25.77 | -5.94 | 3.61 | -1.38 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.80 | 1.80 | 2.18 | 1.38 | 1.61 | 4.09 | 1.27 | 3.35 | 2.42 | 0.96 | 1.43 |
| Quick Ratio | 1.59 | 1.59 | 2.00 | 1.04 | 1.33 | 3.75 | 0.94 | 3.07 | 1.27 | 0.63 | 1.18 |
| Cash Ratio | 0.89 | 0.89 | 1.04 | 0.37 | 0.70 | 3.10 | 0.13 | 2.50 | 1.81 | 0.22 | 0.60 |
| Asset Turnover | — | 1.41 | 0.98 | 0.88 | 0.75 | 0.66 | 1.59 | 1.06 | 1.92 | 2.84 | 2.54 |
| Inventory Turnover | 2.58 | 2.58 | 2.96 | 1.66 | 1.79 | 1.13 | 1.41 | 1.62 | 1.09 | 1.13 | 2.71 |
| Days Sales Outstanding | — | 42.47 | 57.07 | 47.92 | 55.77 | 45.20 | 53.08 | 41.42 | 10.28 | 48.43 | 52.64 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 3.4% | 0.3% | 1.1% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | 1.5% | — |
| FCF Yield | 1.0% | 1.1% | — | — | — | — | — | — | 4.1% | — | 9.3% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.4% | 0.3% | 1.1% |
| Shares Outstanding | — | $9M | $8M | $8M | $8M | $7M | $6M | $2M | $2M | $2M | $1M |
Includes 30+ ratios · 25 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SMTI stock.
Sanara MedTech Inc.'s current P/E ratio is -5.7x. The historical average is 65.1x.
Sanara MedTech Inc.'s current EV/EBITDA is 21.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 42.8x.
Sanara MedTech Inc.'s return on equity (ROE) is -167.5%. The historical average is -56.2%.
Based on historical data, Sanara MedTech Inc. is trading at a P/E of -5.7x. Compare with industry peers and growth rates for a complete picture.
Sanara MedTech Inc. has 90.1% gross margin and 8.9% operating margin.
Sanara MedTech Inc.'s Debt/EBITDA ratio is 4.1x, indicating high leverage. A ratio above 4x may signal elevated financial risk.